Bachem Holding AG
BANB
Kedudukan dalam Saham
#2516
Bachem Holding AG serves pharmaceutical and biotechnology companies globally,... Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Harga Saham
$100.60
Modal Pasaran
$7.54B
Perubahan (1 hari)
-1.49%
Perubahan (1 tahun)
49.53%
Negara
CH
Perdagangan Bachem Holding AG (BANB)
Kategori
Healthcare
Pendapatan untuk Bachem Holding AG (BANB)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Bachem Holding AG, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Bachem Holding AG dari 2002 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2025 | $197.08M | 31.67% |
| 2024 | $149.68M | 1.35% |
| 2023 | $147.69M | 21.84% |
| 2022 | $121.22M | -15.88% |
| 2021 | $144.11M | 42.32% |
| 2020 | $101.26M | 62.26% |
| 2019 | $62.40M | 12.36% |
| 2018 | $55.54M | 11.92% |
| 2017 | $49.63M | 10.07% |
| 2016 | $45.08M | 20.90% |
| 2015 | $37.29M | 1.92% |
| 2014 | $36.59M | 12.98% |
| 2013 | $32.38M | 52.96% |
| 2012 | $21.17M | 62.51% |
| 2011 | $13.03M | -61.93% |
| 2010 | $34.22M | -23.54% |
| 2009 | $44.76M | -29.32% |
| 2008 | $63.33M | -12.95% |
| 2007 | $72.75M | 49.11% |
| 2006 | $48.79M | 30.20% |
| 2005 | $37.47M | 1.17% |
| 2004 | $37.04M | -5.60% |
| 2003 | $39.24M | 21.47% |
| 2002 | $32.30M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
